Cellular hierarchies predict drug response in acute myeloid leukemia

被引：0
|
作者：
Raffel, Simon [1 ]
Velten, Lars [2 ,3 ]
Haas, Simon [4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ]
机构：
[1] Univ Hosp Heidelberg, Dept Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany
[2] Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Dr Aiguader 88, Barcelona 08003, Spain
[3] Univ Pompeu Fabra UPF, Barcelona, Spain
[4] Charite Univ Med Berlin, Berlin Inst Hlth BIH, Berlin, Germany
[5] Helmholtz Assoc, Max Delbr uck Ctr Mol Med, Berlin Inst Med Syst Biol, Berlin, Germany
[6] Charite Univ Med Berlin, Berlin, Germany
[7] Free Univ Berlin, Berlin, Germany
[8] Humboldt Univ, Dept Hematol Oncol & Canc Immunol, Berlin, Germany
[9] Heidelberg Inst Stem Cell Technol & Expt Med HI S, Heidelberg, Germany
[10] Deutsch Krebsforschungszentrum DKFZ, Div Stem Cells & Canc, Heidelberg, Germany
[11] DKFZ ZMBH Alliance, Heidelberg, Germany
[12] German Canc Consortium DKTK, Heidelberg, Germany
来源：
CANCER CELL | 2022年 / 40卷 / 09期
关键词：
STEMNESS SCORE; RISK;
D O I：
10.1016/j.ccell.2022.08.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：917 / 919
页数：3
相关论文
共 50 条
  • [21] Lysosome-related genes predict acute myeloid leukemia prognosis and response to immunotherapy
    Wan, Peng
    Zhong, Liang
    Yu, Lihua
    Shen, Chenlan
    Shao, Xin
    Chen, Shuyu
    Zhou, Ziwei
    Wang, Meng
    Zhang, Hongyan
    Liu, Beizhong
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [22] Cellular drug resistance profiles in childhood acute myeloid leukemia:: differences between FAB types and comparison with acute lymphoblastic leukemia
    Zwaan, CM
    Kaspers, GJL
    Pieters, R
    Woerden, NLR
    den Boer, ML
    Wünsche, R
    Rottier, MMA
    Hählen, K
    van Wering, ER
    Janka-Schaub, GE
    Creutzig, U
    Veerman, AJP
    BLOOD, 2000, 96 (08) : 2879 - 2886
  • [23] CELLULAR PHARMACOKINETICS OF DAUNORUBICIN - RELATIONSHIPS WITH THE RESPONSE TO TREATMENT IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA
    KOKENBERG, E
    SONNEVELD, P
    SIZOO, W
    HAGENBEEK, A
    LOWENBERG, B
    JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (05) : 802 - 812
  • [24] Antibody–drug conjugates in acute myeloid leukemia
    David A Scheinberg
    Joseph G Jurcic
    Peter Maslak
    Nature Clinical Practice Oncology, 2006, 3 : 238 - 239
  • [25] Drug resistance in childhood acute myeloid leukemia
    Styczynski, J.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2007, 8 (02) : 59 - 75
  • [26] Recent drug approvals for acute myeloid leukemia
    Lai, Catherine
    Doucette, Kimberley
    Norsworthy, Kelly
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [27] Assessment of drug resistance in acute myeloid leukemia
    Funato, T
    Harigae, H
    Abe, S
    Sasaki, T
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2004, 4 (05) : 705 - 713
  • [28] Recent drug approvals for acute myeloid leukemia
    Catherine Lai
    Kimberley Doucette
    Kelly Norsworthy
    Journal of Hematology & Oncology, 12
  • [29] Drug Repurposing for the Treatment of Acute Myeloid Leukemia
    Andresen, Vibeke
    Gjertsen, Bjorn T.
    FRONTIERS IN MEDICINE, 2017, 4
  • [30] Mechanisms of drug resistance in acute myeloid leukemia
    Zhang, Jing
    Gu, Yan
    Chen, Baoan
    ONCOTARGETS AND THERAPY, 2019, 12 : 1937 - 1945
12345